PDCD1 and melanoma: Despite substantial progress in early diagnosis and the clinical deployment of immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1, melanoma continues to exhibit pronounced inter- and intra-tumoral heterogeneity, therapeutic refractoriness, and frequent dissemination at distant sites, contributing to dismal outcomes in advanced-stage disease (3, 4).